GlassScriptPhysician profile
Kristin Moore
NPI 1447257530
$15,174.96
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,167 · 2020: $1,701 · 2021: $2,842 · 2022: $3,029 · 2023: $2,996 · 2024: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,413 · Consulting Fee: $22.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,412.87 |
| Consulting Fee | $22.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,285.29 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,772.38 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $1,547.58 | 2019-2024 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $1,534.36 | 2020-2024 | Cuvitru, Takhzyro |
| Genzyme Corporation | $1,185.97 | 2019-2024 | |
| Grifols USA, LLC | $860.57 | 2019-2024 | Xembify |
| Biocryst US Sales Co., LLC | $556.76 | 2021-2024 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $511.49 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $466.94 | 2019-2024 | |
| Optinose US, INC. | $461.09 | 2019-2024 | |
| Amgen INC. | $445.69 | 2021-2024 | Tezspire |
| Kaleo, INC. | $348.66 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $341.97 | 2019-2024 | Ruconest |
| Pfizer INC. | $333.45 | 2019-2024 | |
| Shire North American Group INC | $284.66 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $229.33 | 2022-2024 | Ayvakit |
| Incyte Corporation | $212.31 | 2021-2024 | Opzelura |
| Genentech USA, INC. | $131.96 | 2019-2023 | Xolair |
| Octapharma USA, INC. | $119.68 | 2019-2023 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $100.83 | 2020-2021 | |
| Leo Pharma INC. | $94.73 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.45 | 2019-2020 | |
| Mylan Specialty L.P. | $47.33 | 2020-2021 | |
| Stryker Corporation | $28.28 | 2019-2020 | |
| Apria Healthcare LLC | $25.43 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.60 | 2019 | |
| Adma Biomanufacturing LLC | $22.77 | 2024 | |
| Biocryst Pharmaceuticals, INC. | $22.24 | 2020 | |
| Aimmune Therapeutics, INC. | $21.20 | 2021 | |
| Hikma Pharmaceuticals USA | $20.16 | 2024 | Ryaltris |
| Alk-Abello, INC | $19.84 | 2019 | |
| Medtronic, INC. | $15.57 | 2024 | Propel |
| Phadia US INC. | $13.39 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.